XANAX XR SUMMARY
XANAX® XR CIV
(alprazolam) extended-release tablets
XANAX XR Tablets contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.
XANAX XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
This claim is supported on the basis of two positive studies with XANAX XR conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES).
Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes.
The longer-term efficacy of XANAX XR has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient.
|
NEWS HIGHLIGHTS
Published Studies Related to Xanax XR (Alprazolam)
Does oral alprazolam affect ventilation? A randomised, double-blind, placebo-controlled trial. [2009.05]
The respiratory effects of benzodiazepines have been controversial...
Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. [2007.05]
CONCLUSIONS: The acute impairing effects of alprazolam XR 1 mg on driving and psychomotor functions were generally less, as compared to its immediate-release equivalent, but still of sufficient magnitude to increase the risk of becoming involved in traffic accidents.
Current approaches to the pharmacologic treatment of anxiety disorders. [2007]
Despite their high prevalence, the anxiety disorders are underdiagnosed and undertreated.
Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. [2007]
BACKGROUND/AIMS: Benzodiazepines (BZDs) are the most effective of the psychotropic drugs in the treatment of anxiety disorders. Tolerance has been reported for the majority of BZDs after chronic administration. However, little attention has been paid to the possibility that tolerance might be present after the intermittent oral administration of BZDs. The objectives of the present study were to assess tolerance development after the administration of two intermittent single oral doses of alprazolam given 15 days apart in healthy volunteers, and to compare the results obtained using measures from different domains: neurophysiological, psychomotor and subjective... CONCLUSIONS: The administration of two single oral doses of alprazolam, 2 weeks apart in healthy volunteers, yielded the same PKs on both occasions, but significant changes were observed in the PD profile. Acute tolerance was observed after the second administration. Two patterns of acute tolerance development were obtained: (1) impairments of psychomotor performance and relative beta-1 activity, and (2) subjective assessments and relative alpha activity. (c) 2007 S. Karger AG, Basel.
Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. [2006.11]
Little is known about effects of commonly used anxiolytic drugs on psychologically evoked responses of two major stress systems, the hypothalamic-pituitary-adrenal (HPA) and the sympathetic-adrenal-medullary (SAM) axis. The purpose of the present study was to assess effects of the anxiolytic alprazolam on responses of the HPA and the SAM axes to a standardized psychosocial stress protocol, the Trier Social Stress Test (TSST)...
Clinical Trials Related to Xanax XR (Alprazolam)
A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks [Terminated]
The purpose of this study is to assess the long-term safety and tolerability of alprazolam
extended release (XR) in adolescents with panic disorder, with or without agoraphobia, or in
anxiety disorder with panic attacks. Efficacy, population pharmacokinetics of alprazolam XR
and the relationship between alprazolam XR plasma concentrations and efficacy outcomes will
also be evaluated.
Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's alprazolam 1 mg
Extended-release tablets to Pharmacia & Upjohn's Xanax XR 1 mg tablets following a single,
oral 3 mg (3 x 1 mg) dose administered under fasting conditions.
Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's alprazolam
Extended-release 3 mg tablets to Pharmacia & Upjohn's Xanax XR® 3 mg tablets following a
single, oral 3 mg (1 x 3 mg) dose administered under fed conditions.
Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's alprazolam 3 mg
Extended-release tablets to Pharmacia & Upjohn's Xanax XR® 3 mg tablets following a single,
oral 3 mg (1 x 3 mg) dose administered under fasting conditions.
A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder [Terminated]
The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and
tolerability of alprazolam XR in adolescents with panic disorder.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Xanax XR has an overall score of 8. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Xanax XR review by 38 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Anxiety Rapid Onset |
| Dosage & duration: | | .5 (dosage frequency: once daily xr) for the period of 20-30 for effectiveness |
| Other conditions: | | Sudden anxiety for 1st time |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | Xanax XR .5 once daily for 2 days. This med works within 20-30 mins. A good solution for fast anxiety relief, as opposed to waiting 2 weeks for it to "settle" into your system. I think I might have done fine with .25 instead of the .50.
However, just reading about other people's anxiety accounts and Xanax has given me anxiety! |
| Side effects: | | A wee lethargic, but welcome feeling compared to... you know dying and hyperventilating. :) Definately tired. Maybe some minor bowel disturbances.
I am concerned about withdrawal so plan to take it on an as needed basis only! |
| Comments: | | Xanax XR .5 once daily for 2 days now. |
|
|
|
Page last updated: 2009-10-20
|
